{"entity":{"id":"ficlatuzumab","kind":"drug","name":"Ficlatuzumab","aka":[],"tldr":"Ficlatuzumab is an experimental monoclonal antibody from AVEO Pharmaceuticals in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.","summary":"Ficlatuzumab (AV-299) is a monoclonal antibody developed by AVEO Pharmaceuticals. The sponsor describes its target as HGF (hepatocyte growth factor), which OnCo does not yet have a target page for. The sponsor states: A humanized hepatocyte growth factor (HGF) inhibitory IgG1 monoclonal antibody that blocks HGF signalling, distinct from EGFR-targeted agents such as cetuximab. ClinicalTrials.gov describes the intervention as: Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06064877 (A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma), in head and neck squamous cell carcinoma. The largest, NCT06064877, plans to enrol 410 participants with primary completion expected 2027-08. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Ficlatuzumab","url":"https://clinicaltrials.gov/search?intr=AV-299"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["aveo"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06064877"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"AV-299","modality":"monoclonal antibody","mechanism":"A humanized hepatocyte growth factor (HGF) inhibitory IgG1 monoclonal antibody that blocks HGF signalling, distinct from EGFR-targeted agents such as cetuximab.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ficlatuzumab/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"company":[{"id":"aveo","kind":"company","name":"AVEO Oncology (LG Chem)","route":"/companies/aveo/"}],"trial":[{"id":"nct06064877","kind":"trial","name":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06064877/"}],"target":[{"id":"hgf","kind":"target","name":"HGF","route":"/targets/hgf/"}]}}